Section Arrow
XNCR.NASDAQ
- Xencor
Quotes are at least 15-min delayed:2026/01/08 06:17 EST
Pre Market
Last
 --
-- (--)
Bid
14.5
Ask
15.37
High -- 
Low -- 
Volume -- 
Regular Hours (Closed)
Last
 14.95
+0.89 (+6.33%)
Day High 
15.4 
Prev. Close
14.06 
1-M High
18.3 
Volume 
1.60M 
Bid
14.5
Ask
15.37
Day Low
13.9875 
Open
14.08 
1-M Low
13.77 
Market Cap 
1.00B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 15.09 
20-SMA 15.82 
50-SMA 15.53 
52-W High 23.8409 
52-W Low 6.92 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.73/-2.51
Enterprise Value
1.18B
Balance Sheet
Book Value Per Share
8.76
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
110.49M
Operating Revenue Per Share
2.03
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
ASBPAspire Biopharma Holdings Inc.0.1256+0.0206+19.62%-- 
Pre Market 0.1215 -0.0041 -3.26%
ERASErasca5.17+1.54+42.42%-- 
Pre Market 4.52 -0.65 -12.57%
RXRXRecursion Pharmaceuticals4.86+0.31+6.81%-- 
Pre Market 4.77 -0.09 -1.85%
VTYXVentyx Biosciences13.73+3.68+36.62%-- 
Pre Market 13.74 +0.01 +0.07%
GLUEMonte Rosa Therapeutics23.28+7.27+45.41%54.09PE
Pre Market 22.99 -0.29 -1.25%
Industry overview quotes are at least 15 minutes delayed
Business Description
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.